Organizational Focus and Operational Model

As an investment management entity, Undeterred Capital operates primarily through private venture funds, pooling capital from institutional investors and limited partners to take equity positions in emerging technology ventures. The firm positions itself as a high-conviction partner at the earliest stages of formation, frequently acting as the lead or co-lead investor.

Stage and Capital Allocation Profile

• Inception to Seed Stage: Over 80% of Undeterred Capital's portfolio investments are committed at the pre-seed stage or earlier, often working with founders immediately upon incorporation or academic spin-out.
• Check Sizing: Typical initial investment check sizes range between $500,000 and $1,000,000 per portfolio company.
• Syndicate Role: The firm frequently acts as the lead or co-lead investor, pricing rounds, drafting term sheets, taking board or board observer seats, and assisting founders in filling out their investor syndicates.

Core Investment Theses

The entity limits its deployment to scientific and industrial disciplines where defensible intellectual property and proprietary engineering solve complex physical-world problems.

1. Biological Platforms

The biological platforms vertical encompasses tools, infrastructure, and applied technologies that leverage biological mechanisms to produce goods, therapeutics, or advanced materials: * Synthetic Biology and Genetic Engineering: Engineering biology to build novel bio-based products, enzymes, and engineered microorganisms. * AI and Computational Tools for Drug Discovery: Utilizing machine learning algorithms, molecular modeling, and bioinformatics to accelerate the discovery and validation of pharmaceutical compounds. * Materials Science and Sustainable Biomaterials: Developing alternatives to conventional petrochemicals and synthetic plastics using bio-manufactured polymers and cellular structures. * Healthcare and Discovery Tools: Designing hardware, assays, and consumables that improve cellular analysis, genomic testing, and clinical research.

2. Applied Robotics and Hard Tech

The applied robotics vertical focuses on physical hardware, actuation systems, and automation software designed to execute complex, real-world tasks across diverse operating environments: * Autonomy and Navigation Systems: Vision and machine intelligence systems enabling automated machines to navigate physical terrain, unstructured indoor spaces, or outer space. * Chemical and Laboratory Automation: Hardware platforms that automate wet-lab assays, pharmaceutical compounding, and chemical synthesis. * Swarm Robotics: Distributed multi-agent robotic systems cooperating to perform large-scale logistical, environmental, or agricultural operations. * Biomanufacturing Hardware: Specialized automation equipment engineered to safely scale the production of advanced cell therapies, gene therapies, and engineered biologics.

Products, Services, and Value-Add Programs

Undeterred Capital does not sell retail goods or software licenses. Its commercial products and services exist within the venture capital framework, delivered directly to portfolio founders and prospective startups:

1. Venture Equity Financing (Primary Product)

The core offering of Undeterred Capital is institutional risk capital delivered via preferred equity instruments, convertible notes, or Simple Agreements for Future Equity (SAFE notes): * Pre-Seed and Incorporation Financing: Seed-stage funding rounds that allow academic researchers, scientists, and engineers to transition laboratory IP into an operating corporation. * Follow-On Capital: Targeted reserve capital earmarked to participate in subsequent Series A and Series B financing rounds for outperforming portfolio assets.

2. Operational and Commercialization Advisory Services

Deep tech and bio-platform startups face extended developmental timelines, heavy capital requirements, and technical de-risking. Undeterred Capital provides structured advisory services to mitigate these friction points: * Technical and Scientific De-risking: Evaluating experimental protocols, milestone roadmaps, and laboratory validation schedules to ensure founders hit value-inflection milestones before their runway concludes. * Regulatory and Compliance Guidance: Assisting biotechnology and robotics companies through compliance frameworks, including FDA clearance pathways, environmental certifications, and export control regulations. * Commercial Go-to-Market Strategy: Structuring pilot agreements, paid customer evaluations, joint development agreements (JDAs), and commercial licensing contracts with large enterprise partners.

3. Talent Acquisition and Organizational Scaling

Building hard-science companies requires interdisciplinary teams bridging academic research and industrial engineering: * Technical Recruiting: Sourcing candidates across specialized disciplines such as computational biology, systems architecture, embedded hardware engineering, and bioprocess engineering. * Fractional and Executive Placement: Assisting founders in appointing experienced chief executives, fractional CFOs, and regulatory affairs directors during early corporate structuring.

4. Downstream Fundraising and Syndicate Structuring

• Investor Network Access: Facilitating direct introductions to late-stage venture capital firms, corporate venture capital (CVC) arms, and sovereign wealth vehicles for future funding rounds.
• Pitch Deck Refinement and Pitch Preparation: Direct coaching on communicating technical breakthroughs to generalist institutional investors.

Representative Portfolio Engagements

Undeterred Capital's operational footprint is reflected through its investments across deep tech, life sciences, and robotics, including companies such as:

• Newlight Technologies: Commercializing carbon-negative biomaterials derived from ocean-based microorganisms.
• Portal Biotechnologies: Developing cellular delivery and discovery tools for biological therapeutics.
• Parallel Bio: Creating human tissue-based immunology models to test therapeutics and replace animal testing.
• TRIC Robotics: Engineering autonomous agricultural robotics utilizing ultraviolet light treatments to replace chemical pesticides on crops.
• AstroForge: Commercializing deep-space exploration and asteroid mining technology.
• Cascade Space: Developing spacecraft systems and commercial space technologies.
• Circe Bioscience: Developing gas-fermentation technologies to produce fats and molecules from greenhouse gases.
• Shinkei Systems: Building automated robotics systems for sustainable and humane seafood harvesting.

Leadership and Governance

Undeterred Capital's operational management is led by individuals with direct backgrounds in deep tech entrepreneurship, scientific research, and venture finance:

• Joe Wilson (Founder and Managing Partner): Previously co-founded and served as COO of Multiply Labs (a pharmaceutical robotics venture originating out of MIT and funded by Y Combinator and Lux Capital) and worked as a venture partner at MarsBio.
• Emily Lindberg, Ph.D. (Principal and Head of Research): Holds a Ph.D. in Biomechanics from the University of California, Berkeley, with background in cell biology and materials science; directs the firm's scientific diligence and thesis research.
• Kylie Trettner, Ph.D. (Associate): Holds a Ph.D. in Chemical Engineering from the University of Southern California, with research experience spanning biophysics and applied commercialization.
• Paul Scott (Chief Financial Officer): Oversees legal, regulatory, audit, fund accounting, and compliance operations, with more than two decades of fund administration experience across biotech venture platforms.